Abstract:The long-term mortality and morbidity of patients with severe fever with thrombocytopenia syndrome (SFTS) remain unclear. This retrospective cohort study was conducted using the National Health Insurance Service dataset on hospitalized patients with SFTS aged ≥20 years between 2016 and 2021 (n = 1,217). Each SFTS case was matched with three controls hospitalized for non-SFTS-related diseases using propensity score matching. The all-cause mortality of patients with SFTS was evaluated during the one-year follow-up and compared with that of controls. Post-discharge events were investigated to determine the effects of SFTS on post-acute sequelae. Finally, 1,105 patients with SFTS and 3,315 controls were included. Patients with SFTS had a higher risk of death during the one-year follow-up than that of controls (hazard ratio [HR], 2·26; 95% confidence interval [CI], 1·82–2·81). Thirty-day mortality was significantly higher in the SFTS group (HR, 3·99; 95% CI, 3·07–5·19) than in the control group. An increased risk of death after 31–365 days was observed among controls, though this difference was significant only among patients in their 80s (HR, 0·18; 95% CI, 0·06–0·57). For post-discharge events, patients in the SFTS group exhibited a higher risk of readmission (HR, 1·17; 95% CI, 1·04–1·32) and emergency room visit (HR, 2·32; 95% CI, 1·96–2·76) than those in the control group. SFTS induces a higher risk of short-term mortality and post-acute sequelae in hospitalized patients during a one-year follow-up than non-SFTS-related diseases. Our results provide guidance for the management of SFTS. Severe fever with thrombocytopenia syndrome (SFTS) is a life-threatening viral disease, which has expanded beyond Asian countries. However, most studies have focused on the short-term mortality of patients with SFTS, and knowledge of their long-term outcomes is limited. This nationwide cohort study evaluated long-term outcomes of hospitalized patients with SFTS between 2016 and 2021 using the national dataset. We found that hospitalized patients with SFTS had higher one-year mortality (HR, 2.26) than those without SFTS. An increased mortality risk was attributed to death in the first 30 days of hospitalisation (HR, 3.99). Although the long-term mortality (31–365 days) did not differ between patients with and without SFTS, except for those in their 80s, patients with SFTS suffered from post-acute events, including readmission (HR, 1.17) or emergency room visit (HR, 2.32) during the one-year follow-up. SFTS is an emerging infectious disease that demands attention. The disease burden extends beyond the acute phase, with patients often experiencing ongoing health problems even after hospital discharge. Our findings underscore the post-acute burden of SFTS and offer valuable insights for the development of effective management plans for acute and post-acute illnesses in patients with SFTS.

Analysis of Changes in Viral Load and Inflammatory Cytokines, as Well as the Occurrence of Secondary Infections, in SFTS Patients Treated with Specific Treatments: A Prospective Multicenter Cohort Study

Effects of steroid therapy in patients with severe fever with Thrombocytopenia syndrome: A multicenter clinical cohort study

One-year mortality and morbidities of severe fever with thrombocytopenia syndrome compared with other diseases: A nationwide cohort study in South Korea

Severe Fever with Thrombocytopenia Syndrome in South Korea, 2016-2021: Clinical Features of Severe Progression and Complications

Effect of Severe Fever With Thrombocytopenia Syndrome Virus Genotype on Disease Severity, Viral Load, and Cytokines in South Korea

Concurrent Measurement of Dynamic Changes in Viral Load, Serum Enzymes, T Cell Subsets, and Cytokines in Patients with Severe Fever with Thrombocytopenia Syndrome

Differential short-term and long-term metabolic and cytokine responses to infection of severe fever with thrombocytopenia syndrome virus

Clinical Characteristics and Immune Status of Patients with Severe Fever with Thrombocytopenia Syndrome.

Changes in peripheral blood cytokines in patients with severe fever with thrombocytopenia syndrome

Therapeutic plasma exchange combined with ribavirin to rescue critical SFTS patients

Dynamic Changes in the Immunological Characteristics of T Lymphocytes in Surviving Patients with Severe Fever with Thrombocytopenia Syndrome (SFTS).

Dyslipidemia in severe fever with thrombocytopenia syndrome patients: A retrospective cohort study

Prognostic value of clinical and immunological markers in acute phase of SFTS virus infection.

Circulating Regulatory T Cells In Patients With Severe Fever With Thrombocytopenia Syndrome

The clinical and immunological characteristics in fatal severe fever with thrombocytopenia syndrome virus (SFTSV) infection

Meta-analysis of the Clinical and Laboratory Parameters of SFTS Patients in China.

CD4 T cell loss and Th2 and Th17 bias are associated with the severity of severe fever with thrombocytopenia syndrome (SFTS).

Characterization of Clinical Features and Outcome for Human-to-human Transmitted Severe Fever with Thrombocytopenia Syndrome

Acute kidney injury as a prognostic marker in severe fever with thrombocytopenia syndrome

A longitudinal sampling study of transcriptomic and epigenetic profiles in patients with thrombocytopenia syndrome

Serum lipidome reveals lipid metabolic dysregulation in severe fever with thrombocytopenia syndrome